Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 brodalumab induction and maintenance therapy in moderate to severe plaque psoriasis
ChiCTR2000039699Phase 4Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in plaque psoriasis comparing Brodalumab 210 mg Q2W with Placebo (2 arms). Primary endpoint: PASI 75 response at Week 12. Started Nov 2020; status: recruiting.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2000039699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039699.